Unit of Anti-Viral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
PLoS One. 2011 Jan 28;6(1):e16563. doi: 10.1371/journal.pone.0016563.
Although DNA plasmid and virus-like particle (VLP) vaccines have been individually tested against highly pathogenic avian influenza (HPAI) H5N1 viruses, the combination of both vaccines into a heterologous prime-boost strategy against HPAI H5N1 viruses has not been reported before.
METHODOLOGY/PRINCIPAL FINDINGS: We constructed DNA plasmid encoding H5HA (A/Shenzhen/406H/06, subclade 2.3.4) and generated VLP expressing the same H5HA and N1NA. We then compared neutralizing antibody responses and immune protection elicited with heterologous DNA-VLP, homologous DNA-DNA and VLP-VLP prime-boost strategies against HPAI H5N1 viruses in mice. We demonstrate that DNA-VLP elicits the highest neutralizing antibody titers among the three prime-boost strategies, whereas DNA-DNA elicits higher neutralizing antibody titers than VLP-VLP. We show that although all three prime-boost strategies protect mice from death caused by 10 MLD(50) of homologous and heterologous H5N1 challenge, only DNA-VLP and DNA-DNA protect mice from infection as manifested by no weight loss and no lung pathology. In addition, we show that although DNA-VLP and DNA-DNA protect mice from death caused by 1,000 MLD(50) of homologous H5N1 challenge, only DNA-VLP protects mice from infection. Moreover, we show that after 1,000 MLD(50) of heterologous H5N1 challenge, while all mice in PBS, VLP-VLP and DNA-DNA died, 3 of 6 mice in DNA-VLP actually survived. Finally, we show that DNA-VLP completely protects mice from infection after 1,000 MLD(50) of homologous H5N1 challenge even when the challenge was administrated at 60 days post the boost.
CONCLUSIONS/SIGNIFICANCE: These results provide strong support for clinical evaluation of heterologous DNA-VLP prime-boost strategy as a public health intervention against a possible H5N1 pandemic.
尽管 DNA 质粒和病毒样颗粒(VLP)疫苗已分别针对高致病性禽流感(HPAI)H5N1 病毒进行了测试,但将这两种疫苗组合成针对 HPAI H5N1 病毒的异源初免-加强策略尚未见报道。
方法/主要发现:我们构建了编码 H5HA(A/Shenzhen/406H/06,亚系 2.3.4)的 DNA 质粒,并生成了表达相同 H5HA 和 N1NA 的 VLP。然后,我们比较了异源 DNA-VLP、同源 DNA-DNA 和 VLP-VLP 初免-加强策略在小鼠中针对 HPAI H5N1 病毒产生的中和抗体反应和免疫保护作用。我们证明,在三种初免-加强策略中,DNA-VLP 可诱导最高的中和抗体滴度,而 DNA-DNA 比 VLP-VLP 诱导更高的中和抗体滴度。我们表明,尽管所有三种初免-加强策略都能保护小鼠免受同源和异源 H5N1 10 MLD(50)挑战的致死,但只有 DNA-VLP 和 DNA-DNA 能保护小鼠免受感染,表现为无体重减轻和无肺部病理学。此外,我们表明,尽管 DNA-VLP 和 DNA-DNA 能保护小鼠免受同源 H5N1 1,000 MLD(50)挑战的致死,但只有 DNA-VLP 能保护小鼠免受感染。此外,我们表明,在异源 H5N1 1,000 MLD(50)挑战后,尽管 PBS、VLP-VLP 和 DNA-DNA 组中的所有小鼠都死亡,但在 DNA-VLP 组中有 3 只小鼠实际上存活下来。最后,我们表明,即使在加强后 60 天进行挑战,DNA-VLP 也能完全保护小鼠免受同源 H5N1 1,000 MLD(50)挑战的感染。
结论/意义:这些结果为临床评估异源 DNA-VLP 初免-加强策略作为针对可能的 H5N1 大流行的公共卫生干预措施提供了有力支持。